Sarah Trenfield and Abdul Basit look at the potential applications of 3D-printing technology to create personalised drug therapies in fields such as multiple drug therapy and paediatric/geriatric care and introduce FabRx’s 3D-printing system, which can produce formulations to suit a variety of situations.
Stabilitech Recognised by WHO, seeks £6m funding to make oral SARS-COV-2 vaccine available by end of 2020
Stabilitech Biopharma, which is developing OraPro-COVID-19, an oral coronavirus vaccine, has been formally recognised on the international stage by the WHO as a vaccine developer, and seeks £6 million to fund clinical trials and manufacturing required to make the vaccine available by the end of 2020.
Martti Hedman, Chief Executive of Colorcon, has released a statement in which he confirmed that Colorcon is continuing its business activities, which had been categorised as essential and life sustaining by authorities around the world. He noted that Colorcon materials and coatings are used in some of the drugs that are being evaluated for use to treat COVID-19.
Lexaria Bioscience Expands Pharma Division for development of Lipophilic Antivirals against COVID-19
Although paediatric drugs are traditionally administered in a liquid formulation, recent studies suggest that orally disintegrating mini-tablets may be a more accurate, convenient and less messy dosage form. Don Barbieri explores this method and reviews two case studies looking at whether quality standards can be met and the importance of taste in paediatric formulations.
Carmen Popescu summarises the benefits and applications of orally dissolving film dosage forms, with claims supported by two case studies, one demonstrating the suitability of ODFs for the delivery of micro and nanoparticles, the other showing how this property of ODFs exhibits promise as a next-generation immunisation system.
Nozer Mehta, James P Gilligan and William Stern summarise the different technologies that have been in development for oral delivery of peptides through the gastro-intestinal mucosal surfaces via the transcellular or the paracellular pathways and describe the results of several long-term clinical studies on the oral delivery of salmon calcitonin.